Atossa Therapeutics, Inc.
ATOS
$5.16
-$0.34-6.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.15% | 9.92% | 2.78% | -1.14% | -3.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.47% | 11.42% | -1.90% | -10.25% | -11.97% |
| Operating Income | -34.47% | -11.42% | 1.90% | 10.25% | 11.97% |
| Income Before Tax | -36.33% | -12.15% | -10.84% | 11.27% | 15.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.33% | -12.15% | -10.84% | 11.27% | 15.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.33% | -12.15% | -10.84% | 11.27% | 15.25% |
| EBIT | -34.47% | -11.42% | 1.90% | 10.25% | 11.97% |
| EBITDA | -34.49% | -11.47% | 1.87% | 10.23% | 11.96% |
| EPS Basic | -32.84% | -9.44% | -8.92% | 11.95% | 15.09% |
| Normalized Basic EPS | -42.39% | -16.86% | -2.34% | 8.56% | 12.08% |
| EPS Diluted | -32.84% | -9.44% | -8.92% | 11.95% | 15.09% |
| Normalized Diluted EPS | -42.39% | -16.86% | -2.34% | 8.56% | 12.08% |
| Average Basic Shares Outstanding | 2.63% | 2.39% | 1.71% | 0.85% | -0.18% |
| Average Diluted Shares Outstanding | 2.63% | 2.39% | 1.71% | 0.85% | -0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |